Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-025 and BB-031 in Healthy Volunteers
NCT07202663Phase 1Completed
- Sponsor
- Basking Biosciences
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BB-025 in anticoagulation reversal (3 arms), sponsored by Basking Biosciences. Primary endpoint: Safety as assessed by adverse events (AEs) at Day 28. Started Nov 2025; status: completed.
02
Drugs
BB-025
03
Conditions
anticoagulation reversal
Beyond the preview
Go deeper on NCT07202663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202663.